Related references
Note: Only part of the references are listed.The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
Dario Giugliano et al.
CARDIOVASCULAR DIABETOLOGY (2022)
Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan
Ryotaro Bouchi et al.
JOURNAL OF DIABETES INVESTIGATION (2022)
Clinical Research Using the Large Health Insurance Claims Database
Yoh Takekuma et al.
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN (2022)
Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source
Yoshihiro Noguchi et al.
BRIEFINGS IN BIOINFORMATICS (2021)
Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials
Edoardo Mannucci et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2021)
Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study
Sheriza Baksh et al.
SCIENTIFIC REPORTS (2021)
Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidase-4 inhibitors in treatment-naive patients with type 2 diabetes in Japan
Takeshi Horii et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Comparison of effectiveness and drug cost between dipeptidyl peptidase-4 inhibitor and biguanide as the first-line anti-hyperglycaemic medication among Japanese working generation with type 2 diabetes
Noriko Ihana-Sugiyama et al.
JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2020)
Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease
Sheriza N. Baksh et al.
PLOS ONE (2020)
Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population
Ken Suzuki et al.
NATURE GENETICS (2019)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis
Sean L. Zheng et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
Gian Paolo Fadini et al.
DIABETES THERAPY (2018)
Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
Gian Paolo Fadini et al.
DIABETES THERAPY (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus
Masayuki Kaneko et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2016)
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System
E. Raschi et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2016)
Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus
Shuo-Ming Ou et al.
ANNALS OF INTERNAL MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Metformin-inclusive Therapy Reduces the Risk of Stroke in Patients with Diabetes: A 4-Year Follow-up Study
Yuan-Yang Cheng et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2014)
Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States
Ronald C. W. Ma et al.
YEAR IN DIABETES AND OBESITY (2013)
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
Jie Hong et al.
DIABETES CARE (2013)
Economic Costs of Diabetes in the U.S. in 2012
DIABETES CARE (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis
Ronan Roussel et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension
R. Huxley et al.
OBESITY REVIEWS (2008)
Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study
M Peyrot et al.
DIABETIC MEDICINE (2005)
Share Paper
